Log in | Register

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shockOpen access

Simon Finfer| V. Marco Ranieri| B. Taylor Thompson| Philip S. Barie| Jean-François Dhainaut| Ivor S. Douglas| Bengt Gårdlund| John C. Marshall| Andrew Rhodes
Special Article
Volume 34, Issue 11 / November , 2008

Pages 1935 - 1947

Abstract

The role of drotrecogin alfa (activated) (DAA) in severe sepsis remains controversial and clinicians are unsure whether or not to treat their patients with DAA. In response to a request from the European Medicines Agency, Eli Lilly will sponsor a new placebo-controlled trial and history suggests the results will be subject to great scrutiny. An academic steering committee will oversee the conduct of the study and will write the study manuscripts. The steering committee intends that the study will be conducted with the maximum possible transparency; this includes publication of the study protocol and a memorandum of understanding which delineates the role of the sponsor. The trial has the potential to provide clinicians with valuable data but patients will only benefit if clinicians have confidence in the conduct, analysis and reporting of the trial. This special article describes the process by which the trial was developed, major decisions regarding trial design, and plans for independent analysis, interpretation and reporting of the data.

Keywords

References

  1. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35:1244–1250
    • View reference on PubMed
    • View reference on publisher's website
  2. Martin GS, Mannino DM, Eaton S, Moss M (2003) The Epidemiology of Sepsis in the United States from 1979 through 2000. New Engl J Med 348:1546–1554
    • View reference on PubMed
    • View reference on publisher's website
  3. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R (2002) Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28:108–121
  4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310
    • View reference on PubMed
    • View reference on publisher's website
  5. Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, Fang Q, Xu Q, Wang D, Jin Y, Yuan S, Wang J, Du Z, Sun Y, Fang X (2007) Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35:2538–2546
    • View reference on PubMed
    • View reference on publisher's website
  6. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J, the ANZICS CTG Sepsis Investigators (2004) Adult population incidence of severe sepsis in Australian and New Zealand Intensive Care Units. Intensive Care Med 30:589–596
  7. Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, la-Kokko TI, Kolho E, Rintala EM (2007) Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 33:435–443
  8. Linde-Zwirble WT, Angus DC (2004) Severe sepsis epidemiology: sampling, selection, and society. Crit Care 8:222–226
    • View reference on PubMed
    • View reference on publisher's website
  9. Padkin A, Goldfrad C, Brady A, Young D, Black N, Rowan K (2003) Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 31:2332–2338
    • View reference on PubMed
    • View reference on publisher's website
  10. Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, Montani C, Magni E (1995) The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21(Suppl 2):S244–S249
  11. Russell JA (2006) Management of Sepsis. N Engl J Med 355:1699–1713
    • View reference on PubMed
    • View reference on publisher's website
  12. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. [comment]. New Engl J Med 344:699–709
    • View reference on PubMed
    • View reference on publisher's website
  13. Matthay MA (2001) Severe sepsis—a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344:759–762
    • View reference on PubMed
    • View reference on publisher's website
  14. Mackenzie I, Lever A (2007) Management of sepsis. BMJ 335:929–932
    • View reference on PubMed
    • View reference on publisher's website
  15. Mackenzie AF, Bartelink AK (2007) Management of sepsis. N Engl J Med 356:1179
    • View reference on PubMed
  16. European Medicines Agency (2002) Marketing authorization. Drotrecogin alfa (activated). Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/xigris/247102en7.pdf. Accessed 8 November 2007
  17. Anti-Infective Advisory Committee. (2001) FDA briefing document: drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, BLA#125029/0. Food and Drug Administration, September 12, 2001. Available from http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1.htm. Accessed 11 August 2007
  18. Food and Drug Administration (2001) CDER 2001 meeting documents. Available from http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Anti-Infective. Accessed 11 August 2007
  19. Siegel JP (2002) Assessing the use of activated protein c in the treatment of severe sepsis. N Engl J Med 347:1030–1034
    • View reference on PubMed
    • View reference on publisher's website
  20. Food and Drug Administration (2002) Approval Letter - Drotrecogin alfa (activated), Xigris. Available from http://www.fda.gov/cder/foi/appletter/2001/droteli112101L.pdf. Accessed 6 September 2007
  21. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL, the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group (2005) Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death. N Engl J Med 353:1332–1341
    • View reference on PubMed
    • View reference on publisher's website
  22. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, bd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369:836–843
    • View reference on PubMed
    • View reference on publisher's website
  23. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277
    • View reference on PubMed
    • View reference on publisher's website
  24. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33:426–434
  25. Warren HS, Suffredini AF, Eichacker PQ, Munford RS (2002) Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347:1027–1030
    • View reference on PubMed
    • View reference on publisher's website
  26. Mackenzie AF (2005) Activated protein C: do more survive? Intensive Care Med 31:1624–1626
  27. Friedrich JO, Adhikari NK, Meade MO (2006) Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Crit Care 10:145
    • View reference on PubMed
    • View reference on publisher's website
  28. Opal SM (2007) Can we RESOLVE the treatment of sepsis? Lancet 369:803–804
    • View reference on PubMed
    • View reference on publisher's website
  29. Gardlund B (2006) Activated protein C (XigrisR) treatment in sepsis: a drug in trouble. Acta Anaesthesiol Scand 50:907–910
    • View reference on PubMed
    • View reference on publisher's website
  30. Marti-Carvajal A, Salanti G, Cardona AF (2007) Human recombinant activated protein C for severe sepsis. Cochrane. Database. Syst Rev. Issue 3. Art. No.: CD004388. DOI: 10.1002/14651858.CD004388.pub2
  31. Mueller PS, Montori VM, Bassler D, Koenig BA, Guyatt GH (2007) Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med 146:878–881
    • View reference on PubMed
  32. Pocock SJ (2005) When (not) to stop a clinical trial for benefit. JAMA 294:2228–2230
    • View reference on PubMed
    • View reference on publisher's website
  33. Dombrovskiy V, Martin A, Sunderram J, Paz H (2006) Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals. Am J Health Syst Pharm 63:1151–1156
    • View reference on PubMed
    • View reference on publisher's website
  34. Muller L, Jaber S, Raillard A, Lefrant J (2008) Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study. Intensive Care Med 34:977–979
  35. Schultz MJ, Levi M (2006) Prescription of rh-APC differs substantially among western European countries. Intensive Care Med 32:630–631
  36. Jorgensen AW, Hilden J, Gotzsche PC (2006) Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 333:782–786
    • View reference on PubMed
    • View reference on publisher's website
  37. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167–1170
    • View reference on PubMed
    • View reference on publisher's website
  38. Eichacker PQ, Natanson C, Danner RL (2006) Surviving sepsis—practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 355:1640–1642
    • View reference on PubMed
    • View reference on publisher's website
  39. Singer M (2006) The surviving sepsis guidelines: evidence-based or evidence-biased? Crit Care Resusc 8:244–245
    • View reference on PubMed
  40. University of Versailles (2008) Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHS). Available from http://clinicaltrials.gov/ct2/show/NCT00625209. Accessed 3 January 2008
  41. Higgins TL, Steingrub JS, Tereso GJ, Tidswell MA, McGee WT (2005) Drotrecogin Alfa (Activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes. J Intensive Care Med 20:291–297
    • View reference on publisher's website
  42. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Am College Chest Physicians/Soc Crit Care Med Chest 101:1644–1655
  43. The Australasian Resuscitation in Sepsis Evaluation (ARISE) Investigators, the Australian, New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD) Management Committee (2007) The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resusc 9:8–18
  44. Wheatley K, Clayton D (2003) Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization. Control Clin Trials 24:66–70
    • View reference on PubMed
    • View reference on publisher's website
  45. Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH (2005) Randomized trials stopped early for benefit: a systematic review. JAMA 294:2203–2209
    • View reference on PubMed
    • View reference on publisher's website
  46. Macias WL, Vallet B, Bernard GR, Vincent JL, Laterre PF, Nelson DR, Derchak PA, Dhainaut JF (2004) Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med 32:2385–2391
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement